Minimal Coronary Artery Diseases Risk associated with Celecoxib-DMARDs Drug Combinations

Primary tabs

Minimal Coronary Artery Diseases Risk associated with Celecoxib-DMARDs Drug Combinations

Celecoxib-DMARDs drug combinations were found to be linked to reduced risk of coronary artery diseases (CAD) risk in incident RA patients, confirms recent research published in Current Medical Research and Opinion Journal.

Yao-Min Hung and colleagues conducted a population-based cohort study to evaluate different anti-RA drug combinations and their relation with CAD risk. The drugs used to make combinations were Hydroxychloroquine (HCQ), Sulfasalazine (SSZ), Methotrexate (MTX) and Celecoxib (Cx).

The patients were divided into two groups. The study group consisted of 6260 newly-diagnosed RA patients of age 20 years or more. The reference group included patients who never used  HCQ,  SSZ,  MTX, and  Cx. After managing demographic and other co-morbidities, hazard ratio (HR) was estimated by using Cox proportional hazards model. The spline curve of Scaled Schoenfeld residuals was fitted after the violation of proportionality assumption to evaluate the estimated effect on CAD over time for medicine consumption. The occurrence of CAD as per ICD-9-CM codes was used as study end-point.

Throughout the first period of baseline to 3rd year, 4th and 7 years, the adjusted HR noticed was  0.29, 0.46 and 0.42 for  "Cx," "Cx + HCQ" and  "Cx, HCQ, MTX, and SSZ ever" respectively. However, in the second period of 3, 4, or 7–10 years, HR changed to 1.04, 1.16 and 0.59 respectively.  The "Cx, HCQ, MTX, and SSZ ever" showed constant adjusted HR at 0.12. The overall results showed a time-varying drug effect and reduced CAD risk association with anti-rheumatic medications.


Curr Med Res Opin          


The original title of the article:

Combination effect of anti-rheumatic medications for coronary artery diseases risk in rheumatoid arthritis: a nationwide population-based cohort study


Yao-Min Hung et al.

Exploratory, Hydroxychloroquine, Sulfasalazine, Methotrexate, Celecoxib, Rheumatoid Arthritis, Joints, DMARDs, NSAID, Population-based Cohort Study, Safety
Log in or register to post comments